Daily Endocrinology Research Analysis
Analyzed 70 papers and selected 3 impactful papers.
Summary
Three standout endocrinology studies span mechanisms to practice: a JCI paper identifies GPR182 as a lymphatic endothelial lipoprotein receptor that enables intestinal chylomicron entry, with antibody blockade preventing and treating diet-induced obesity in mice. A Nature Communications study reveals a female-specific hepatic epigenetic network (KDM6A–HNF4A–CREBH) controlling lipoprotein metabolism and atherosclerosis. A double-blind crossover RCT in JAMA Network Open shows once-daily low-dose prednisolone improves bone turnover and cardiometabolic markers vs thrice-daily hydrocortisone in adrenal insufficiency.
Research Themes
- Intestinal lipid absorption and obesity therapeutics
- Sex-specific epigenetic regulation of hepatic cholesterol metabolism
- Optimization of glucocorticoid replacement in adrenal insufficiency
Selected Articles
1. GPR182 is a lipoprotein receptor for dietary fat absorption.
Using genetic ablation, ultrastructural imaging, and antibody blockade, the authors identify GPR182 on lymphatic endothelial cells as a receptor that enables chylomicron entry into lacteals. Loss or pharmacologic inhibition of GPR182 impairs intestinal lipid absorption, increases circulating HDL, and prevents or treats diet-induced obesity in mice.
Impact: This work uncovers a previously unknown receptor-level gateway for dietary fat entry into the lymphatic system and demonstrates therapeutic modulation with monoclonal antibodies, opening a tractable anti-obesity strategy distinct from caloric restriction or CNS appetite pathways.
Clinical Implications: Targeting GPR182 may reduce intestinal fat uptake and improve atherogenic lipoprotein profiles; if safety is confirmed, anti-GPR182 biologics could complement existing anti-obesity therapies and benefit patients with hyperlipidemia. Vigilance for effects on fat-soluble nutrient absorption will be essential.
Key Findings
- GPR182 on lymphatic endothelial cells mediates chylomicron transport into lacteals, enabling dietary fat absorption.
- GPR182 knockout mice show impaired lipid absorption, delayed growth, resistance to diet-induced obesity, and increased HDL.
- Transmission electron microscopy revealed failure of chylomicron entry into the lacteal lumen with GPR182 loss.
- Monoclonal antibody blockade of GPR182 prevents and treats diet-induced obesity in mice.
Methodological Strengths
- Integrated genetic knockout models, ultrastructural TEM imaging, and therapeutic antibody interventions.
- Demonstrated both prevention and treatment efficacy in vivo, supporting translational potential.
Limitations
- Findings are predominantly from mouse models; human validation of GPR182 function in intestinal lymphatics is pending.
- Safety, long-term metabolic consequences, and impacts on fat-soluble nutrient absorption of chronic GPR182 blockade are unknown.
Future Directions: Validate GPR182-mediated transport in human intestinal tissues; assess pharmacology, safety, and nutrient absorption effects of GPR182 inhibitors in large animals; explore indications beyond obesity (e.g., severe hypertriglyceridemia).
The lymphatic system plays a central role in lipid absorption by transporting triglyceride-rich particles called chylomicrons (CMs) from the small intestine to the systemic circulation. However, the molecular mechanism by which CMs get into the intestinal lymphatics is unknown. Here we demonstrated that GPR182, an atypical chemokine receptor in lymphatic endothelial cells, mediates dietary fat absorption. GPR182 knockout mice exhibit a selective increase in circulating high-density lipoproteins and are resis
2. Sex-specific KDM6A-HNF4A-CREBH network controls lipoprotein cholesterol metabolism and atherosclerosis via epigenetic reprograming of hepatocytes.
The study demonstrates that KDM6A safeguards hepatic lipid programs in a sex-specific manner: female but not male hepatocyte Kdm6a loss induces pro-atherogenic lipoprotein profiles and worsens atherosclerosis under genetic/dietary stress. Mechanistically, KDM6A partners with HNF4A to enable CREBH-driven transcription of lipid metabolic genes.
Impact: Identifies an X-linked epigenetic regulator as a female-specific gatekeeper of hepatic cholesterol metabolism and atherosclerosis, offering a mechanistic basis for sex-informed cardiometabolic precision medicine.
Clinical Implications: Highlights sex as a biological variable in dyslipidemia and atherosclerosis; suggests that KDM6A/CREBH pathway activity could inform risk stratification and inspire female-focused epigenetic or transcriptional therapies.
Key Findings
- Female hepatocyte-specific Kdm6a deletion induces pro-atherogenic lipoprotein profiles and increases atherosclerosis; males are largely unaffected.
- In human female liver cells, KDM6A reduction disrupts lipoprotein regulatory gene programs linked to cardiovascular risk.
- KDM6A cooperates with HNF4A to activate chromatin and enable CREBH-dependent transcription of lipid metabolic genes.
Methodological Strengths
- Cross-species validation integrating human primary/engineered cells and mouse models with sex-stratified analyses.
- Mechanistic dissection of chromatin and transcriptional networks linking epigenetic regulation to functional atherosclerosis outcomes.
Limitations
- Preclinical findings without interventional human data; translational relevance requires clinical validation.
- Focus on hepatocytes may not capture multi-organ contributors to sex differences in atherogenesis.
Future Directions: Assess KDM6A pathway biomarkers in human cohorts for sex-specific CVD risk; explore small-molecule or epigenetic modulators of KDM6A/CREBH; design sex-stratified preclinical therapeutic studies.
The liver is a central organ controlling lipid and cholesterol metabolism and plays a key role in regulating lipoprotein profiles and cardiovascular disease risk. Males and females show clear differences in cholesterol handling and susceptibility to atherosclerosis, but the molecular basis for these sex-specific effects remains incompletely understood. Here we show that the X-linked histone demethylase 6 A (KDM6A) is essential for maintaining healthy cholesterol metabolism in the liver. Reducing KDM6A levels
3. Prednisolone Once Daily vs Hydrocortisone Thrice Daily in Hypoadrenalism: A Randomized Clinical Trial.
In a double-blind crossover RCT (n=46), once-daily low-dose prednisolone reduced bone turnover markers (osteocalcin, urinary NTX, P1NP) compared with thrice-daily hydrocortisone. Prednisolone also led to modest reductions in weight, BMI, waist circumference, and HbA1c, without differences in safety or quality of life over 4-month treatment periods.
Impact: Provides randomized, blinded comparative evidence supporting once-daily low-dose prednisolone as a metabolically favorable alternative to standard hydrocortisone regimens in adrenal insufficiency.
Clinical Implications: Prednisolone 2–5 mg once daily may simplify glucocorticoid replacement while improving bone turnover and metabolic markers; clinicians may consider individualized switching, with longer-term fracture, cardiovascular, and mortality outcomes still needed before guideline changes.
Key Findings
- Prednisolone slowed bone turnover vs hydrocortisone: lower carboxylated and undercarboxylated osteocalcin, urinary NTX, and P1NP.
- Prednisolone reduced weight (−1.87 kg), BMI, waist circumference, and HbA1c compared with hydrocortisone.
- No significant differences in safety measures or quality-of-life assessments between treatments over 4-month periods.
Methodological Strengths
- Double-blind, randomized crossover design minimizes inter-individual variability and bias.
- Comprehensive biomarker assessment across bone turnover and cardiometabolic parameters.
Limitations
- Modest sample size (n=46) and short treatment durations (4 months per period) limit detection of hard clinical outcomes.
- Surrogate endpoints; lack of long-term fracture, cardiovascular, or mortality data.
Future Directions: Conduct larger, longer-duration pragmatic RCTs powered for fractures, cardiovascular events, and mortality; evaluate adherence, adrenal crisis rates, and patient-reported outcomes under real-world dosing.
IMPORTANCE: Adrenal insufficiency is conventionally treated with daily multiple-dose hydrocortisone, and once-daily low-dose prednisolone is an alternative for glucocorticoid replacement. Clinical trials comparing once-daily low-dose prednisolone with thrice-daily hydrocortisone are lacking. OBJECTIVE: To examine the differences in metabolism and bone turnover in patients receiving hydrocortisone vs prednisolone for adrenal insufficiency. DESIGN, SETTING, AND PARTICIPANTS: This double-blind, crossover randomized clin